Intravenous Immunoglobulin Global Market Report 2025

Description

Intravenous immunoglobulin therapy serves as a treatment for individuals with immunodeficiencies, administered through intravenous infusion. The infusion liquid derives from purified immunoglobulins sourced from healthy donors, rigorously cleansed to eliminate any potential blood-borne infections or impurities.

Key categories of intravenous immunoglobulins encompass IgG, IgM, IgA, IgE, and IgD. IgG, the prevalent immunoglobulin in bodily fluids, plays a pivotal role in safeguarding against bacterial and viral infections. Its application involves reinforcing the body's innate defense mechanisms. These products find distribution channels across hospital and retail pharmacies, serving various medical needs like hypogammaglobulinemia, CIDP, primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, among others. The end-users span hospitals, clinics, and home care setups.

The intravenous immunoglobulin market research report is one of a series of new reports from The Business Research Company that provides intravenous immunoglobulin market statistics, including intravenous immunoglobulin industry global market size, regional shares, competitors with an intravenous immunoglobulin market share, detailed intravenous immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous immunoglobulin industry. This intravenous immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $14.66 billion in 2024 to $15.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to treatment of primary immunodeficiency disorders, management of neurological disorders, rising geriatric population, advancements in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, pediatric immunodeficiency treatment.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $22.01 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing incidence of autoimmune disorders, ongoing research in immunology, rising healthcare expenditure, growth in cancer incidence, innovation in immunoglobulin products, personalized medicine approaches. Major trends in the forecast period include primary immunodeficiency disorders (PIDD) treatment, rapid technological innovations, strategic collaborations and partnerships, advancements in manufacturing processes, indications in neurology, use in hematology, advances in immunotherapy.

The growing geriatric population is anticipated to propel the intravenous immunoglobulin market in the coming years. The geriatric population is defined as individuals aged 65 and older. As people age, their immune systems often become less effective, leading to a deficiency in antibodies. Consequently, there is a heightened need for immunoglobulins to provide these necessary antibodies. This increasing demand for intravenous immunoglobulins contributes to the market's growth. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, reported that the population of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, the proportion of this age group within the overall population is expected to grow from 17% to 23% during the same timeframe. Therefore, the expanding geriatric population is set to drive the growth of the intravenous immunoglobulin market.

The rising prevalence of rheumatoid arthritis (RA) is expected to drive the growth of the intravenous immunoglobulin (IVIG) market in the coming years. RA is a chronic autoimmune condition that leads to inflammation, pain, swelling, and stiffness in the joints. If untreated, it can result in significant joint damage and disability. IVIG, a blood product containing antibodies from healthy donors, can help mitigate the inflammatory processes that contribute to joint damage in RA patients. For instance, in June 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that approximately 456,000 Australians (1.9%) are estimated to have rheumatoid arthritis. In 2022, RA was responsible for 2.0% of the total disease burden and 16% of the overall burden of musculoskeletal diseases. Furthermore, in July 2022, the National Rheumatoid Arthritis Society (NRAS), a UK-based nonprofit organization, estimated that over 450,000 individuals in the UK are living with rheumatoid arthritis, with the most common onset age being between 40 and 60, or slightly older for men. Thus, the increasing prevalence of rheumatoid arthritis is driving growth in the intravenous immunoglobulin (IVIG) market.

Product innovation is a significant trend gaining traction in the intravenous immunoglobulin (IVIG) market. Key players in the industry are concentrating on developing new products, such as liquid immune globulin formulations, to treat immunodeficiency diseases and maintain their competitive edge. For example, in December 2023, GC Pharma, a pharmaceutical company based in South Korea, launched Alyglo, a sterile, ready-to-use liquid formulation that has received approval from the U.S. Food and Drug Administration (FDA). This product contains 10% immunoglobulin G (IgG), providing 100 mg/mL of protein, of which at least 96% is human IgG derived from pooled human plasma. Alyglo is specifically indicated for treating primary humoral immunodeficiency (PI) in adults aged 17 years and older, addressing conditions such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Major companies in the intravenous immunoglobulin (IVIG) market are concentrating on launching innovative products, such as plasma-derived medicines, and securing approvals from federal agencies like the U.S. Food and Drug Administration (FDA) to enhance their competitive position. The introduction of an FDA-approved innovative IVIG solution represents the official endorsement of a new intravenous immunoglobulin therapy by the FDA for treating specific medical conditions. For instance, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products, announced that it received its first FDA approval for Yimmugo, designed to treat primary immunodeficiencies (PIDs). As an intravenous immunoglobulin, Yimmugo contains pooled human plasma-derived immunoglobulin G (IgG), which is essential for providing immune support to patients with PIDs. This approval aligns with the growing demand for plasma-derived therapies, emphasizing the need for effective treatments for patients with weakened immune systems. Yimmugo expands Grifols' existing portfolio of intravenous and subcutaneous immunoglobulins, offering more options for patients dependent on these vital medications.

In February 2024, Ridgemont Equity Partners, a U.S.-based equity investment firm, acquired American Outcomes Management for an undisclosed amount. This acquisition supports Ridgemont's strategic focus on the expanding specialty infusion market, which is fueled by an aging population with chronic conditions and an increasing demand for at-home treatment options. American Outcomes Management is a U.S.-based provider of intravenous immunoglobulin (IVIG) infusion therapy.

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the intravenous immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous immunoglobulin market consists of sales of intravenous immunoglobulin used for treating people with antibody deficiencies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intravenous Immunoglobulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intravenous immunoglobulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intravenous immunoglobulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous immunoglobulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: IgG (Immunoglobulin G); IgM (Immunoglobulin M); IgA (Immunoglobulin A); IgE (Immunoglobulin E); IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
3) By Application: Hypogammaglobulinemia; Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); Primary Immunodeficiency Diseases; Myasthenia Gravis; Multifocal Motor Neuropathy; Other Applications
4) By End-User: Hospitals; Clinics; Home Care
Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG; Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM; Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA; Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE; Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD; Specific IgD
Companies Mentioned: Bio Products Laboratory Limited; Biotest AG; China Biologic Products Holdings Inc.; CSL Behring; Grifols S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r22727

1. Executive Summary

2. Intravenous Immunoglobulin Market Characteristics

3. Intravenous Immunoglobulin Market Trends And Strategies

4. Intravenous Immunoglobulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Intravenous Immunoglobulin Growth Analysis And Strategic Analysis Framework

5.1. Global Intravenous Immunoglobulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Intravenous Immunoglobulin Market Growth Rate Analysis
5.4. Global Intravenous Immunoglobulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Intravenous Immunoglobulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Intravenous Immunoglobulin Total Addressable Market (TAM)

6. Intravenous Immunoglobulin Market Segmentation

6.1. Global Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IgG (Immunoglobulin G)
IgM (Immunoglobulin M)
IgA (Immunoglobulin A)
IgE (Immunoglobulin E)
IgD (Immunoglobulin D)
6.2. Global Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Other Distribution Channels
6.3. Global Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency Diseases
Myasthenia Gravis
Multifocal Motor Neuropathy
Other Applications
6.4. Global Intravenous Immunoglobulin Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Care
6.5. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin G (IgG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal IgG
Specific IgG
6.6. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin M (IgM), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal IgM
Specific IgM
6.7. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin A (IgA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal IgA
Specific IgA
6.8. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin E (IgE), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal IgE
Specific IgE
6.9. Global Intravenous Immunoglobulin Market, Sub-Segmentation Of Immunoglobulin D (IgD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Normal IgD
Specific IgD

7. Intravenous Immunoglobulin Market Regional And Country Analysis

7.1. Global Intravenous Immunoglobulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Intravenous Immunoglobulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intravenous Immunoglobulin Market

8.1. Asia-Pacific Intravenous Immunoglobulin Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intravenous Immunoglobulin Market

9.1. China Intravenous Immunoglobulin Market Overview
9.2. China Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intravenous Immunoglobulin Market

10.1. India Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intravenous Immunoglobulin Market

11.1. Japan Intravenous Immunoglobulin Market Overview
11.2. Japan Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intravenous Immunoglobulin Market

12.1. Australia Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intravenous Immunoglobulin Market

13.1. Indonesia Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intravenous Immunoglobulin Market

14.1. South Korea Intravenous Immunoglobulin Market Overview
14.2. South Korea Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intravenous Immunoglobulin Market

15.1. Western Europe Intravenous Immunoglobulin Market Overview
15.2. Western Europe Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intravenous Immunoglobulin Market

16.1. UK Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intravenous Immunoglobulin Market

17.1. Germany Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intravenous Immunoglobulin Market

18.1. France Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intravenous Immunoglobulin Market

19.1. Italy Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intravenous Immunoglobulin Market

20.1. Spain Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intravenous Immunoglobulin Market

21.1. Eastern Europe Intravenous Immunoglobulin Market Overview
21.2. Eastern Europe Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intravenous Immunoglobulin Market

22.1. Russia Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intravenous Immunoglobulin Market

23.1. North America Intravenous Immunoglobulin Market Overview
23.2. North America Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intravenous Immunoglobulin Market

24.1. USA Intravenous Immunoglobulin Market Overview
24.2. USA Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intravenous Immunoglobulin Market

25.1. Canada Intravenous Immunoglobulin Market Overview
25.2. Canada Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intravenous Immunoglobulin Market

26.1. South America Intravenous Immunoglobulin Market Overview
26.2. South America Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intravenous Immunoglobulin Market

27.1. Brazil Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intravenous Immunoglobulin Market

28.1. Middle East Intravenous Immunoglobulin Market Overview
28.2. Middle East Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intravenous Immunoglobulin Market

29.1. Africa Intravenous Immunoglobulin Market Overview
29.2. Africa Intravenous Immunoglobulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Intravenous Immunoglobulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Intravenous Immunoglobulin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intravenous Immunoglobulin Market Competitive Landscape And Company Profiles

30.1. Intravenous Immunoglobulin Market Competitive Landscape
30.2. Intravenous Immunoglobulin Market Company Profiles
- 30.2.1. Bio Products Laboratory Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Biotest AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. China Biologic Products Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. CSL Behring Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Grifols S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Intravenous Immunoglobulin Market Other Major And Innovative Companies

31.1. Kedrion SpA
31.2. Shanghai RAAS Blood Products Co. Ltd.
31.3. Octapharma AG
31.4. Takeda Pharmaceutical Company Limited
31.5. Baxter International Inc.
31.6. LFB Biotechnologies SAS
31.7. BDI Pharma Inc.
31.8. Hualan Biological Engineering Inc.
31.9. ADMA Biologics Inc.
31.10. Bharat Serums and Vaccines Limited
31.11. Sanquin Plasma Products B.V.
31.12. Prothya Biosolutions B.V.
31.13. Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
31.14. Pfizer Inc.
31.15. Kedrion Biopharma

32. Global Intravenous Immunoglobulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intravenous Immunoglobulin Market

34. Recent Developments In The Intravenous Immunoglobulin Market

35. Intravenous Immunoglobulin Market High Potential Countries, Segments and Strategies

35.1 Intravenous Immunoglobulin Market In 2029 - Countries Offering Most New Opportunities
35.2 Intravenous Immunoglobulin Market In 2029 - Segments Offering Most New Opportunities
35.3 Intravenous Immunoglobulin Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer